Riskpilot← Back to searchSign inGet full accessCN8 A/S
A/SActiveCVR 42822604Nymøllevej 6Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 20211 employees
Revenue 2025
DKK -1,6M
+2800% vs 2024
EBITDA margin
161.7%
-4589% vs 2024
Equity ratio
99.8%
Financial strength
Net profit 2025
DKK 21,7M
+6% vs 2024
| Revenue | DKK -1,6M | +2800% |
| EBITDA | DKK -2,6M | -4589% |
| Net profit | DKK 21,7M | +6% |
| Total assets | DKK 7,6B | +10% |
| Equity | DKK 7,6B | +10% |
| Employees | 1 | — |
Legal name
CN8 A/S
CVR number
42822604
Legal form
Aktieselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
9. november 2021
Share capital
DKK 1.034.300
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem i forening med en direktør, af to bestyrelsesmedlemmer i forening eller af den
samlede bestyrelse.
Company purpose
Selskabets formål er at eje kapitalandele i andre virksomheder samt al virksomhed, som efter bestyrelsens skøn har forbindelse hermed.
Address
Nymøllevej 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -12 | -36 | -55 | -1.595 |
| Staff expenses | -0 | -0 | -0 | -984 |
| EBITDA | -12 | -36 | -55 | -2.579 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -12 | -36 | -55 | -2.579 |
| Net financials | -0 | 0 | 26.372 | 30.770 |
| Profit before tax | -13 | -36 | 26.317 | 28.191 |
| Tax | -3 | -8 | 5.790 | 6.496 |
| Net profit | -10 | -28 | 20.527 | 21.695 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 43 | 43 | 6.903.810 | 7.579.221 |
| Equity | 30 | 2 | 6.897.978 | 7.566.544 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 41 | 5.832 | 12.675 |
| Total debt | 13 | 41 | 5.832 | 12.675 |
EBITDA margin
-257900000.0%
This company
15.8%
Market median
-1632278581% vs market
20222025
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20222025
Return on equity
0.3%
This company
18.4%
Market median
-98% vs market
20222025
Net profit margin
2169500000.0%
This company
8.1%
Market median
+26783950517% vs market
20222025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20222025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-11-09 – 2022-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LN Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
T&W Medical A/S | Company | 66.7% | 66.7% | 2024 |
LUNDBECKFOND INVEST A/S | Company | 15.0% | 15.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LUNDBECKFONDEN
CN8 A/S Board members of CN8 A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Nørgaard | Chief Executive Officer | 0 companies |
| Jan Tøpholm | Board of Directors | 0 companies |
| Julian Tøpholm | Chairman | 0 companies |
| Adam Westermann | Board of Directors | 0 companies |
| Peter Rothaus Rothausen | Board of Directors | 0 companies |
| Arne Due-Hansen | Deputy Chairman | 0 companies |